NORTH KINGSTOWN, R.I., June 15 At the forefront of the ongoing effort to enhance addiction treatment outcomes, one leading Rhode Island Company has announced the next-generation clinical laboratory diagnostics tool designed to assist clinicians.
Dominion Diagnostics (Dominion), a privately-held clinical urine drug testing laboratory, today announced the release of its new Comprehensive Analysis of Reported Drugs (CARD)(TM) results, a unique clinical laboratory reporting service that provides clinicians with accurate testing results and analytical feedback to augment the assessment and monitoring of an individual's drug use upon admission and throughout the course of addiction treatment.
Dominion developed its CARD(TM) reporting service to create a highly personalized clinical report by correlating an individual's prescribed medication use and self-reported drug misuse with its state-of-the-art diagnostic testing.
CARD(TM)( )utilizes laboratory results from validated quantitative urine drug testing profiles for commonly abused illicit and prescription drugs and/or their metabolites, as well as biological markers and commercial adulterant screening (i.e., creatinine, specific gravity, pH, and oxidants) to ensure specimen validity. CARD(TM)( )employs a supplied list of prescribed treatment-related medications and self-reported non-prescribed drug misuse, along with documented pharmaceutical and pharmacokinetic references backed by Dominion's expert Clinical Services team of pharmacists.
Dominion's CARD(TM) results provide data to support and measure a treatment program's ability to reduce morbidity in substance abuse, improve retention in treatment, and promote the use of evidence-based practice for individuals suffering from addiction and mental health disorders, in line with ongoing initiatives supported by the Substance Abuse and Mental Health Services Agency (SAMHSA).
"CARD(TM) is a new service that will assist clinicians in tailoring addiction treatment services to each individual, thus improving treatment retention and outcomes by providing a more complete picture of their clients' treatment progress," said Dominion's Vice President of Addiction Services, Mary Hauser, MA. "It is the first objective laboratory reporting tool of its kind."
For treatment programs, CARD(TM) provides a mechanism for reporting summary data that reflects client's medication compliance and treatment progress on a quarterly or annual basis. This data can be used by treatment programs to report outcomes to a wide variety of private and governmental funding sources.
ABOUT DOMINION DIAGNOSTICS
Dominion Diagnostics is a premier provider of comprehensive clinical quantitative urine drug testing, medication monitoring and support services nationwide. For over 13 years, Dominion has provided services to thousands of clients in a variety of medical specialties, including Addiction Treatment, Behavioral Health, Pain Medicine, Primary Care, and Hospital Systems. Dominion is supported by a world-class team that shares a commitment to clinical and operational excellence. For more information about Dominion, please visit www.dominiondiagnostics.com.
Julie K. Lenahan, MBA, Director of Marketing, 401/667-0876, [email protected]
SOURCE Dominion Diagnostics